Literature DB >> 22529203

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

S Holland1, S D Silberstein, F Freitag, D W Dodick, C Argoff, E Ashman.   

Abstract

OBJECTIVE: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: Are nonsteroidal anti-inflammatory drugs (NSAIDs) or other complementary treatments effective for migraine prevention?
METHODS: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications for migraine prevention.
RESULTS: The author panel reviewed 284 abstracts, which ultimately yielded 49 Class I or Class II articles on migraine prevention; of these 49, 15 were classified as involving nontraditional therapies, NSAIDs, and other complementary therapies that are reviewed herein. RECOMMENDATIONS: Petasites (butterbur) is effective for migraine prevention and should be offered to patients with migraine to reduce the frequency and severity of migraine attacks (Level A). Fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, MIG-99 (feverfew), magnesium, riboflavin, and subcutaneous histamine are probably effective for migraine prevention (Level B). Treatments considered possibly effective are cyproheptadine, Co-Q10, estrogen, mefenamic acid, and flurbiprofen (Level C). Data are conflicting or inadequate to support or refute use of aspirin, indomethacin, omega-3, or hyperbaric oxygen for migraine prevention. Montelukast is established as probably ineffective for migraine prevention (Level B).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22529203      PMCID: PMC3335449          DOI: 10.1212/WNL.0b013e3182535d0c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis.

Authors:  B S Rao; D G Das; V R Taraknath; Y Sarma
Journal:  Neurol India       Date:  2000-09       Impact factor: 2.117

2.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

3.  A randomized, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine.

Authors:  O S Eftedal; S Lydersen; G Helde; L White; A O Brubakk; L J Stovner
Journal:  Cephalalgia       Date:  2004-08       Impact factor: 6.292

4.  Low-dose aspirin for migraine prophylaxis in women.

Authors:  I M Benseñor; N R Cook; I M Lee; M J Chown; C H Hennekens; J E Buring
Journal:  Cephalalgia       Date:  2001-04       Impact factor: 6.292

5.  An extract of Petasites hybridus is effective in the prophylaxis of migraine.

Authors:  W Grossman; H Schmidramsl
Journal:  Altern Med Rev       Date:  2001-06

6.  Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo.

Authors:  A Pradalier; P Bakouche; G Baudesson; A Delage; G Cornaille-Lafage; J M Launay; P Biason
Journal:  Cephalalgia       Date:  2001-10       Impact factor: 6.292

7.  A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study.

Authors:  H C Diener; E Hartung; J Chrubasik; S Evers; J Schoenen; A Eikermann; G Latta; W Hauke
Journal:  Cephalalgia       Date:  2001-03       Impact factor: 6.292

8.  Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine.

Authors:  Briant E Burke; Richard D Olson; Barry J Cusack
Journal:  Biomed Pharmacother       Date:  2002-08       Impact factor: 6.529

9.  Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.

Authors:  A I Scher; R B Lipton; W F Stewart; M Bigal
Journal:  Cephalalgia       Date:  2010-02-01       Impact factor: 6.292

10.  Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.

Authors:  R O Millán-Guerrero; R Isais-Millán; S Barreto-Vizcaíno; I Gutiérrez; L Rivera-Castaño; B Trujillo-Hernández; L M Baltazar
Journal:  Eur Neurol       Date:  2008-02-08       Impact factor: 1.710

View more
  68 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

Review 2.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

3.  Phytomedicines in the Treatment of Migraine.

Authors:  Thilinie Rajapakse; William Jeptha Davenport
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 4.  Nutraceuticals and Behavioral Therapy for Headache.

Authors:  Rebecca Barmherzig; Thilinie Rajapakse
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-10       Impact factor: 5.081

Review 5.  Improving medication adherence in migraine treatment.

Authors:  Elizabeth K Seng; Jeanetta A Rains; Robert A Nicholson; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2015-06

Review 6.  Complementary and Integrative Medicine for Neurologic Conditions.

Authors:  Rebecca Erwin Wells; Vanessa Baute; Helané Wahbeh
Journal:  Med Clin North Am       Date:  2017-06-23       Impact factor: 5.456

Review 7.  Current and investigational drugs for the prevention of migraine in adults and children.

Authors:  Frederick G Freitag; Derrick Shumate
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

8.  Nutraceuticals in Acute and Prophylactic Treatment of Migraine.

Authors:  Oved Daniel; Alexander Mauskop
Journal:  Curr Treat Options Neurol       Date:  2016-04       Impact factor: 3.598

Review 9.  Refining the Benefit/Risk Profile of Anti-Epileptic Drugs in Headache Disorders.

Authors:  Michael J Marmura; Aliza S Kumpinsky
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 10.  Preventive Migraine Treatment.

Authors:  Stephen D Silberstein
Journal:  Continuum (Minneap Minn)       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.